Business Review.com
By PBR staff writer
Trial to last 12 month
Pfizer and Medivation, a biopharmaceutical company reported the initiation of a 12-month, Phase III clinical trial of the investigational drug Dimebon. The study, known as Concert, is designed to evaluate the safety and efficacy of Dimebon when added to ongoing treatment with donepezil HCI tablets, for patients with mild-to-moderate Alzheimer’s disease.
The Concert study is part of a broad, Phase III clinical development program for Dimebon. The study builds on data from a small-scale safety and tolerability trial of Dimebon added to donepezil, which found the combination to be well tolerated. Concert is designed to complement previous and ongoing studies by further evaluating the efficacy of Dimebon. The Phase III program also includes the confirmatory 6-month Connection study, which is designed to.......read the whole article
For a great resource for those with dementia, caregivers and healthcare professinals, click here
For information on being the best caregiver you can be, click here
For more interesting dementia articles and activities, click here
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment